Pluri (NASDAQ:PLUR) Trading Up 4.9% – What’s Next?

Pluri Inc. (NASDAQ:PLURGet Free Report) shares rose 4.9% during trading on Thursday . The stock traded as high as $4.70 and last traded at $4.70. Approximately 903 shares were traded during mid-day trading, a decline of 84% from the average daily volume of 5,624 shares. The stock had previously closed at $4.48.

Pluri Stock Up 4.9%

The firm has a market capitalization of $38.33 million, a P/E ratio of -0.91 and a beta of 0.66. The firm’s 50-day moving average is $4.91 and its 200 day moving average is $4.78. The company has a debt-to-equity ratio of 51.65, a quick ratio of 0.68 and a current ratio of 0.68.

Pluri (NASDAQ:PLURGet Free Report) last posted its quarterly earnings data on Wednesday, September 17th. The company reported ($2.62) EPS for the quarter, missing the consensus estimate of ($0.73) by ($1.89). The company had revenue of $0.91 million during the quarter, compared to the consensus estimate of $0.40 million. Pluri had a negative net margin of 1,701.19% and a negative return on equity of 4,191.91%.

Institutional Investors Weigh In On Pluri

An institutional investor recently bought a new position in Pluri stock. Jane Street Group LLC purchased a new position in shares of Pluri Inc. (NASDAQ:PLURFree Report) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 10,928 shares of the company’s stock, valued at approximately $47,000. Jane Street Group LLC owned approximately 0.14% of Pluri at the end of the most recent reporting period. Hedge funds and other institutional investors own 16.59% of the company’s stock.

Pluri Company Profile

(Get Free Report)

Pluri Inc, a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production.

Featured Stories

Receive News & Ratings for Pluri Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluri and related companies with MarketBeat.com's FREE daily email newsletter.